1. Home
  2. BGSF vs SER Comparison

BGSF vs SER Comparison

Compare BGSF & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

N/A

Current Price

$5.17

Market Cap

64.0M

ML Signal

N/A

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$2.12

Market Cap

56.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGSF
SER
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.0M
56.4M
IPO Year
2013
2024

Fundamental Metrics

Financial Performance
Metric
BGSF
SER
Price
$5.17
$2.12
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
6.5K
51.7K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
36.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$93,310,000.00
$130,000.00
Revenue This Year
$4.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.14
52 Week Low
$3.26
$1.22
52 Week High
$7.83
$5.83

Technical Indicators

Market Signals
Indicator
BGSF
SER
Relative Strength Index (RSI) 37.97 42.92
Support Level $4.99 $1.69
Resistance Level $5.79 $2.29
Average True Range (ATR) 0.18 0.22
MACD -0.02 -0.06
Stochastic Oscillator 0.00 17.91

Price Performance

Historical Comparison
BGSF
SER

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Share on Social Networks: